CODX
Co-diagnostics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
Consensus Rating "Strong Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CODX
Co-Diagnostics, Inc.
A company that develops robust innovative molecular tools for detection of infectious diseases
Healthcare Equipment and Supplies
04/18/2013
07/12/2017
NASDAQ Stock Exchange
132
12-31
Common stock
2401 S. Foothill Drive, Salt Lake City, Utah 84109
--
Co-diagnostics, Inc., founded on April 18, 2013, is a Utah company headquartered in Salt Lake City, Utah, and is a molecular diagnostic company that has developed and intends to sell molecular diagnostic technologies such as laboratory systems, and manufactures and sells reagents for testing or analytically designed tests using nucleic acid molecules (DNA or RNA).
Earnings Call
Q1/2025
Estimate EPS-0.33
Actual EPS-0.24
Estimate Revenue187.50K
Actual Revenue50.00K
Co-Diagnostics' Q1 2025: Unpacking Contradictions in COVID-19 Test Resubmission and Global Launch Plans
May 19,2025 05:57
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CODX has released its 2025 Q1 earnings. EPS was reported at -0.24, versus the expected -0.33, beating expectations. The chart below visualizes how CODX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CODX has released its 2025 Q1 earnings report, with revenue of 50.28K, reflecting a YoY change of -89.25%, and net profit of -7.53M, showing a YoY change of 19.10%. The Sankey diagram below clearly presents CODX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
